MCK vs MDT

McKesson Corporation (MCK) presents a compelling investment case supported by robust earnings acceleration, consistent top-line growth, and strong analyst conviction, despite operating in a low-margin, capital-intensive distribution model. The stock has delivered exceptional long-term returns with a 373% five-year gain, underpinned by disciplined execution and favorable healthcare logistics tailwinds. While valuation appears stretched on P/E and the balance sheet lacks transparency, MCK trades at a significant discount to peers on price-to-sales and exhibits superior earnings momentum, with YoY EPS growth nearing 40%. Notably, insider selling raises caution, but the broader fundamental trajectory and sector positioning support continued outperformance.

Medtronic exhibits a stable but uninspiring financial profile, evidenced by a Piotroski F-Score of 4/9. While the company maintains a strong balance sheet with a Current Ratio of 2.54 and low Debt/Equity (0.57), it is currently facing a severe technical downtrend and negative earnings growth (-11.8% YoY). There is a significant valuation gap, as the current price of $79.37 trades well above the Graham Number ($55.45) and the growth-based Intrinsic Value ($25.06). The divergence between bullish analyst targets ($108) and bearish insider activity/price action suggests a period of high uncertainty.